| Popis: |
Valentina Perrone,1 Chiara Veronesi,1 Elisa Giacomini,1 Rita Citraro,2 Stefania DellâOrco,3 Fabio Lena,4 Arrigo Paciello,5 Anna Maria Resta,6 Mihaela Nica,7 Daniela Ritrovato,7 Luca Degli Esposti1 1Clicon S.r.l. Società Benefit, Health Economics & Outcomes Research, Bologna, Italy; 2Dipartimento di Scienze della Salute, Università Magna Grecia di Catanzaro, Unitaâ Operativa di Farmaco-logia Clinica e Farmacovigilanza, Azienda Ospedaliero-Universitaria âMater Dominiâ, Catanzaro, Italy; 3ASL Roma 6, Rome, Italy; 4USL Toscana Sud Est, Grosseto, Italy; 5ATS Bergamo, Bergamo, Italy; 6Struttura Complessa di Farmacia Territoriale Area Vasta 1, Fano, Italy; 7Novartis Farma S.p.A, Origgio, Varese, ItalyCorrespondence: Valentina Perrone, CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Via Murri, 9, Bologna, 40137, Italy, Tel +39 3450316494, Email valentina.perrone@clicon.itPurpose: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy.Patients and Methods: An observational study on administrative databases from a sample of Italian entities was carried-out. Between 01/2010â 12/2017, patients with ⥠1 MS diagnosis code (ICD-9-CM:340 and/or exemption code:046) and/or ⥠1 disease-modifying therapies (DMTs) prescription, were included. Among MS-cohort, SPMS patients were identified by ⥠2 hospitalizations or by ⥠2 drug prescriptions related to MS progression. MS patients not fulfilling SPMS criteria were included as RRMS. Mean annual healthcare costs were reported during follow-up and stratified by DMT treatment/untreatment.Results: Overall, 9543 MS patients were included; 8397 with RRMS and 1146 with SPMS. Estimated prevalence of MS was 141.6/100,000 inhabitants (RRMS 124.4/100,000 and SPMS 17.2/100,000). Mean annual cost for untreated and treated patient was respectively: ⬠3638 and ⬠11796 (MS-cohort), ⬠3183 and ⬠11486 (RRMS-cohort), ⬠6317 and ⬠15511 (SPMS-cohort). The first-line DMT treatment duration averaged 27.4 ± 22.8 months; the mean cost was 19004⬠for the whole period. The second-line DMT treatment lasted on average 31.1 ± 24.5 months; the mean cost was 47293⬠for the whole period.Conclusion: This study provided insights into the MS epidemiology in Italy and its economic burden. Healthcare costs associated with MS management were mainly driven by DMTs expenditure. A trend of higher healthcare-resource consumption was observed among SPMS-cohort.Keywords: real-world evidence, clinical practice, multiple sclerosis, epidemiology, healthcare resource consumption |
